Swartz Allison sold $15K of PGNY

Progyny (PGNY) shares fell about 4.5% after the fertility benefits company issued weaker guidance. Q2 revenue rose to $350.5M (+5.3% YoY) and adjusted EPS was $0.55, both above estimates. But it projected $340M revenue for the next quarter, about 3% below consensus, and cut full-year revenue to $1.37B from $1.39B.

Progyny (PGNY) shares fell about 6% after its Q2 earnings. The company reported 5% sales growth, with adjusted EPS up 15% versus expectations. Q3 sales guidance calls for 7% to 11% growth and adjusted earnings are slightly lower sequentially. Gross margins rose 180 bps and covered members increased 7% to 7.2 million.

Progyny (NASDAQ:PGNY) reported Q2 CY2026 revenue of $350.5 million, up 5.3% year on year and 0.6% above analysts’ estimates. Non-GAAP EPS was $0.55, 6.2% above consensus. For next quarter, it guided revenue to $340 million, about 3% below estimates. Shares fell 10.2% to $27.08 after the release.

Progyny, Inc. (PGNY) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991q22026.htm EX-99.1 Document Progyny, Inc. Announces Second Quarter 2026 Results Reports Record Quarterly Revenue, Gross Profit and Adjusted EBITDA Robust Selling Season Activity Continues to Reflect Strong Demand for Women's Health, Family Building Solutions V

Progyny (PGNY) shares rose 3.5% to $31.73 after KeyBanc raised its price target to $35 from $30 and kept an Overweight rating, citing expectations for a strong earnings report and higher future guidance. The article also notes other bullish analyst actions, including Truist raising its target and Canaccord upgrading to Buy.

Progeny (PGNY) director Kevin Gordon sold 5,500 shares for about $137,000, according to the article. The firm reported Q1 revenue of $328 million, up 1.4% YoY, with gross profit rising 10% to $83.1 million. It said client growth and retention were strong aside from a large client loss, and approved a $200 million share repurchase program.